References
- Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69(1):7–34.
- Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–2921.
- Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
- Rebelo A, Michalski CW, Ukkat J, et al. Pancreatic cancer surgery with vascular resection: current concepts and perspectives. J Pancreatol. 2019;2(1):1–5.
- Satoi S, Yamamoto T, Matsui Y. Conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma: where do we stand in 2018? J Pancreatol. 2018;1:25–29.
- Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet. 2016;388(10039):73–85.
- Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279(5350):509–514.
- Shepherd TR, Hard RL, Murray AM, et al. Distinct ligand specificity of the Tiam1 and Tiam2 PDZ domains. Biochemistry. 2011;50(8):1296–1308.
- Matsuo N, Hoshino M, Yoshizawa M, et al. Characterization of STEF, a guanine nucleotide exchange factor for Rac1, required for neurite growth. J Biol Chem. 2002;277(4):2860–2868.
- Chen J-S, Su I-J, Leu Y-W, et al. Expression of T-cell lymphoma invasion and metastasis 2 (TIAM2) promotes proliferation and invasion of liver cancer. Int J Cancer. 2012;130(6):1302–1313.
- Li S, Ou Y, Liu S, et al. The fibroblast TIAM2 promotes lung cancer cell invasion and metastasis. J Cancer. 2019;10(8):1879–1889.
- Yen W-H, Ke W-S, Hung J-J, et al. Sp1-mediated ectopic expression of T-cell lymphoma invasion and metastasis 2 in hepatocellular carcinoma. Cancer Med. 2016;5(3):465–477.
- Zhao Z-Y, Han C-G, Liu J-T, et al. TIAM2 enhances non-small cell lung cancer cell invasion and motility. Asian Pac J Cancer Prev. 2013;14(11):6305–6309.
- Ding M, Li Y, Yang Y, et al. Elevated expression of Tiam1 is associated with poor prognosis and promotes tumor progression in pancreatic cancer. Onco Targets Ther. 2018;11:4367–4375.
- Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102.
- Nagy Á, Lánczky A, Menyhárt O, et al. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8(1):9227
- Bilici A. Prognostic factors related with survival in patients with pancreatic adenocarcinoma. World J Gastroenterol. 2014;20(31):10802–10812.
- Zhang Y, Frampton AE, Cohen P, et al. Tumor infiltration in the medial resection margin predicts survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2012;16(10):1875–1882.
- Katz MH, Hwang R, Fleming JB, et al. Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin. 2008;58(2):111–125.
- Chatterjee D, Katz MH, Rashid A, et al. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2012;36(3):409–417.
- Chiu CY, Leng S, Martin KA, et al. Cloning and characterization of T-cell lymphoma invasion and metastasis 2 (TIAM2), a novel guanine nucleotide exchange factor related to TIAM1. Genomics. 1999;61(1):66–73.
- Yoshizawa M, Hoshino M, Sone M, et al. Expression of stef, an activator of Rac1, correlates with the stages of neuronal morphological development in the mouse brain. Mech Dev. 2002;113(1):65–68.
- Rooney C, White G, Nazgiewicz A, et al. The Rac activator STEF (Tiam2) regulates cell migration by microtubule-mediated focal adhesion disassembly. EMBO Rep. 2010;11(4):292–298.
- Li H, Cui X, Chen D, et al. Clinical implication of Tiam1 overexpression in the prognosis of patients with serous ovarian carcinoma. Oncol Lett. 2016;12(5):3492–3498.
- Yang W, Lv S, Liu X, et al. Up-regulation of Tiam1 and Rac1 correlates with poor prognosis in hepatocellular carcinoma. Jpn J Clin Oncol. 2010;40(11):1053–1059.